Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results

 Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First
                        Quarter 2013 Financial Results

PR Newswire

JERSEY CITY, N.J., May 2, 2013

JERSEY CITY, N.J., May 2, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report
first quarter 2013 financial results after the NASDAQ Global Market closes on
Thursday, May 9. The Company will host a conference call that day at 5:00 p.m.
Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and
highlights for the first quarter and provide a corporate update.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic
callers and +1 (678) 825-8232 for international callers. Please specify to the
operator that you would like to join "Optimer's Financial Results Call." The
conference call will be webcast live under the Investors section of Optimer's
website at www.optimerpharma.com, where it will be archived for 30 days
following the call.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, an FDA-approved macrolide antibacterial drug for the treatment of
Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and
older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in the European Union
where its partner, Astellas Pharma Europe, is commercializing fidaxomicin
under the trade name DIFICLIR™. The Company is exploring marketing
authorization in other parts of the world where C. difficile has emerged as a
serious health problem. Additional information can be found at
http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Website: http://www.optimerpharma.com